drugset / Trial / NCT03397186
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Phase 2
Withdrawn
Fred Hutchinson Cancer Center
Janssen Pharmaceuticals · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelBasic science
Summary
This research trial studies the immune changes following trabectedin in patients with sarcoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Analyzing tumor tissue may help to understand the changes in immune cells in or around the tumor or if there is an increase in immune cells in the tumor after receiving trabectedin.
Timeline
- Start
- 2018-06-19
- Primary completion
- 2021-01-01
- Completion
- 2021-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trabectedin | Small molecule | — | — |